Pallas Capital Advisors LLC Takes $426,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Pallas Capital Advisors LLC bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 671 shares of the biopharmaceutical company's stock, valued at approximately $426,000.

A number of other institutional investors have also recently made changes to their positions in REGN. Pinney & Scofield Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $25,000. OFI Invest Asset Management purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $28,000. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares during the last quarter. Tompkins Financial Corp purchased a new position in Regeneron Pharmaceuticals during the first quarter worth about $32,000. Finally, Curat Global LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target on the stock. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Canaccord Genuity Group raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Finally, Royal Bank of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target on the stock. in a research note on Friday, May 30th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $836.48.

Regeneron Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ:REGN traded up $7.40 during trading hours on Friday, reaching $529.24. The stock had a trading volume of 951,512 shares, compared to its average volume of 875,008. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20. The firm's 50 day moving average is $563.74 and its 200-day moving average is $651.53. The stock has a market capitalization of $57.14 billion, a price-to-earnings ratio of 13.83, a P/E/G ratio of 2.34 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's quarterly revenue was down 3.7% compared to the same quarter last year. During the same period last year, the company earned $9.55 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were given a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.